US 10,888,555 B2
Pharmaceutical composition containing nicotinic acid and/or nicotinamide for beneficially influencing blood lipid levels by modifying the intestinal microbiota
Georg Wätzig, Kiel (DE); and Dirk Seegert, Dänischenhagen (DE)
Assigned to CONARIS RESEARCH INSTITUTE AG, Kiel (DE)
Appl. No. 15/103,410
Filed by CONARIS RESEARCH INSTITUTE AG, Kiel (DE)
PCT Filed Dec. 12, 2014, PCT No. PCT/EP2014/077646
§ 371(c)(1), (2) Date Jun. 10, 2016,
PCT Pub. No. WO2015/086843, PCT Pub. Date Jun. 18, 2015.
Claims priority of application No. 13197283 (EP), filed on Dec. 13, 2013; and application No. 14154543 (EP), filed on Feb. 10, 2014.
Prior Publication US 2017/0027924 A1, Feb. 2, 2017
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/455 (2006.01); A61K 9/00 (2006.01); A61K 9/50 (2006.01); A61K 9/48 (2006.01); A61K 45/06 (2006.01)
CPC A61K 31/455 (2013.01) [A61K 9/0031 (2013.01); A61K 9/0053 (2013.01); A61K 9/4891 (2013.01); A61K 9/5026 (2013.01); A61K 9/5047 (2013.01); A61K 9/5073 (2013.01); A61K 45/06 (2013.01)] 30 Claims
 
1. A pharmaceutical composition for beneficially influencing blood and/or plasma and/or serum lipid levels by beneficially modifying the intestinal microbiota, comprising an active substance selected from nicotinic acid, nicotinamide, nicotinic acid esters, and combinations of any two or more thereof, wherein the composition is formulated for oral administration with controlled and/or delayed release for selective local release of the active substance for topical efficacy in the lower small intestine and/or colon where the intestinal microbiota to be modified are located, thereby beneficially modifying the intestinal microbiota, in an amount effective to increase high density lipoprotein (HDL) blood levels, decrease liver fat content, and/or beneficially influence blood and/or plasma and/or serum lipid levels, wherein the composition is provided with a coating and wherein the controlled and/or delayed release is achieved by the coating.